The FDA granted Vistagen (NASDAQ:VTGN) fast track designation for development of PH10, an investigational nasal sprays, for the treatment of major depressive disorder (MDD). The FDA decision aligns with “our belief in...
Vistagen Therapeutics (NASDAQ:VTGN) announced completion of an interim analysis of PALISADE-2, its second Phase 3 clinical trial assessing drug candidate, PH94B, as an acute treatment of anxiety in adults with social...
VistaGen Therapeutics’ (NASDAQ:VTGN) topline results from its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder did not achieve its primary endpoint, as...
VistaGen Therapeutics (NASDAQ:VTGN) initiated a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety...
VistaGen Therapeutics (NASDAQ:VTGN) announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats demonstrating that a single intranasal administration of radiolabeled carbon-14...
VistaGen Therapeutics (NASDAQ:VTGN) plans to begin a Phase 3 clinical trial in the second quarter with PH94B, a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in...
William Blair upgraded VistaGen Therapeutics (NASDAQ:VTGN) to “outperform” with a fair value estimate of $9, citing a “clearly skewed risk/reward” for the shares. The stock closed at $1.94 on Dec. 31. VistaGen is...
VistaGen Therapeutics (NASDAQ:VTGN) reported positive results from its Phase 2a clinical study of PH10 for treatment of major depressive disorder (MDD). PH10 is a synthetic neurosteroid nasal spray designed to activate...
The FDA cleared VistaGen Therapeutics’ (NASDAQ:VTGN) IND for AV-101 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, enabling the company to proceed with Phase 2...
William Blair downgraded VistaGen Therapeutics (NASDAQ:VTGN) to “market perform” after the Phase 2 ELEVATE study of AV-101 for the adjunctive treatment of major depressive disorder (MDD) failed to meet its primary...